1.00

0.16% 0.0016

After Hours: 1.02 0.02 +2.00%

Lucid Diagnostics Inc (LUCD)

Overview News Price History Financials Discussions Forecast

Lucid Diagnostics Inc stock is traded at $1.00, with a volume of 292.17K. It is up +0.16% in the last 24 hours and up +11.31% over the past month. Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Previous Close:

$0.9984

Open:

24h Volume:

292.17K

Relative Volume:

0.92

Market Cap:

$53.84M

Revenue:

$2.43M

Net Income/Loss:

$-52.67M

P/E Ratio:

-0.6849

EPS:

-1.46

Net Cash Flow:

$-33.04M

1W Performance:

+0.00%

1M Performance:

+11.31%

6M Performance:

+9.18%

1Y Performance:

-27.01%

1-Day Range:

$0.9544

$1.005

1-Week Range:

$0.9499

$1.02

52-Week Range:

$0.6301

$1.58

Lucid Diagnostics Inc Stock (LUCD) Company Profile

Name

Lucid Diagnostics Inc

Sector

Healthcare (1200)

Industry

Medical Devices (153)

Phone

212 949 4319

Address

360 MADISON AVENUE, NEW YORK

Employee

Twitter

Next Earnings Date

2024-11-13

Latest SEC Filings

LUCD's Discussions on Twitter

Compare LUCD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LUCD Lucid Diagnostics Inc	1.00	53.84M	2.43M	-52.67M	-33.04M	-1.46
ABT Abbott Laboratories	118.95	208.18B	41.22B	5.77B	6.49B	2.94
SYK Stryker Corp	388.14	148.70B	21.97B	3.59B	3.21B	6.74
BSX Boston Scientific Corp	90.75	133.32B	15.91B	1.79B	1.89B	0.82
MDT Medtronic Plc	86.27	111.27B	33.00B	4.29B	5.50B	2.71
EW Edwards Lifesciences Corp	72.07	42.66B	6.60B	4.16B	490.10M	2.34

Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-27-21	Initiated	Ascendiant Capital Markets	Buy
Nov-08-21	Initiated	BTIG Research	Buy
Nov-08-21	Initiated	Cantor Fitzgerald	Overweight
Nov-08-21	Initiated	Needham	Buy

Lucid Diagnostics Inc Stock (LUCD) Latest News

Nov 27, 2024

Head-To-Head Review: Lucid Diagnostics (NASDAQ:LUCD) & DIH Holding US (NASDAQ:DHAI) - Defense World

Nov 27, 2024

Nov 23, 2024

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com

Nov 23, 2024

Nov 21, 2024

Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com

Nov 21, 2024

Lucid Diagnostics' SWOT analysis: stock outlook amid reimbursement progress - Investing.com

Nov 21, 2024

Nov 20, 2024

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - Morningstar

Nov 20, 2024

Lucid Diagnostics Announces Agreement for Sale of Senior Secured Convertible Notes - Defense World

Nov 20, 2024

Nov 19, 2024

Lucid Diagnostics Inc. announced that it expects to receive $21.75 million in funding - Marketscreener.com

Nov 19, 2024

Nov 18, 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com

Nov 18, 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - Morningstar

Nov 18, 2024

Nov 15, 2024

LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan

Nov 15, 2024

Cantor Fitzgerald cuts Lucid Diagnostics stock target, overweight on challenges - Investing.com India

Nov 15, 2024

Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald - MarketBeat

Nov 15, 2024

PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Lucid Diagnostics (NASDAQ:LUCD) Provides Business Update and Financial Results - Defense World

Nov 15, 2024

Nov 14, 2024

Lucid Diagnostics' (LUCD) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat

Nov 14, 2024

Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD) - MarketBeat

Nov 14, 2024

PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com

Nov 14, 2024

Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024

PAVmed Provides Business Update and Third Quarter 2024 Financial Results - Kilgore News Herald

Nov 14, 2024

Earnings call: Lucid Diagnostics reports revenue growth and strategic expansion - Investing.com UK

Nov 14, 2024

Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024